ArticleJournal of neuro-oncology2026
Stereotactic radiosurgery for pediatric craniopharyngiomas: a multicenter retrospective study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe role of stereotactic radiosurgery in the management of pediatric craniopharyngiomas remains incompletely defined, particularly with respect to long-term disease control and late treatment-related morbidity. This multicenter study evaluates long-term tumor control and functional outcomes following Gamma Knife radiosurgery (GKRS) in pediatric patients with craniopharyngiomas.
methodsWe retrospectively analyzed 33 pediatric patients (< 18 years) treated with GKRS for residual or recurrent craniopharyngiomas at two independent and experienced neurosurgery centers. Radiological tumor control, recurrence-free survival, visual and endocrinological outcomes were assessed longitudinally. Kaplan-Meier and Cox regression were used to identify factors affecting outcomes.
resultsThe mean age at GKRS was 11.8 years, and the mean tumor volume was 2.3 cm³. The median follow-up was 122.8 months (IQR 79.4-204.3 months). Recurrence-free survival rates at 1, 3, 5, and 10 years were 84.8%, 78.6%, 67.7%, and 48.6%, respectively. Among patients with tumor progression, 66.7% experienced out-of-field recurrence, whereas in-field failures were less common and occurred after a significantly longer interval (63.9 ± 7.7 vs. 19.6 ± 18.3 months; p < 0.01). Visual function remained stable or improved in 97% of patients. One patient experienced visual deterioration (3.0%) related to tumor progression. New-onset endocrinological deficits were uncommon and occurred in patients with pre-existing hypopituitarism (6/27, 22.2% vs. 0/6, 0%, p = 0.003).
conclusionGKRS provides durable control of treated tumor volumes with minimal long-term visual and endocrinological morbidity in selected pediatric patients with craniopharyngiomas. Late disease progression predominantly occurred outside the treated volume, while in-field recurrences were less frequent and characterized by a longer latency.
Indexed as
Identifiers
42118226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.